Search Results - biologics

16 Results

Sort By:

Antibodies against CD5L for therapeutic and diagnostic uses

Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer. UTHealth Ref. No.: 2020-0016 Inventors: Dr. Zhiqiang An and Dr. Ningyan Zhang at UTHealth; Dr. Anil Sood at UT M.D. Anderson Cancer Center Patent Status: PCT application PCT/US2021/025429...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Anil Sood

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Kathryn O'Donnell

Keywords(s):

Category(s): Diagnostics, Oncology, Therapeutics, Biologics

Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.

Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Monoclonal Antibodies Binding to Transferrin Receptor (TfR) for Therapeutic Protein Delivery across Blood-Brain Barrier

Blood-brain barrier (BBB) limits brain entry and is one of the major hurdles in developing antibody and protein-based therapeutics for central nervous system (CNS) diseases. UTHealth researchers identified and engineered monoclonal antibodies binding to transferrin receptor (TfR) but not affecting transferrin (Tf) binding to TfR. An engineered monovalent...

Published: 10/21/2024 | Inventor(s): Zhiqiang An

Keywords(s):

Category(s): Drug Delivery, Therapeutics, Neurology/Neurosurgery, Oncology, Biologics

TREM2 Monoclonal Antibody for Therapeutic and Diagnostic Use

Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. Previous studies in rodent models of AD have shown that mice with increased TREM2 expression have reduced amyloid pathology. UTHealth inventors created and...

Published: 10/21/2024 | Inventor(s): Zhiqiang An

Keywords(s):

Category(s): Therapeutics, Diagnostics, Biologics, Neurology/Neurosurgery

EGFL6 Specific Monoclonal Antibodies for Cancer Diagnostic and Therapeutic Use

Human epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) was discovered in tumors and fetal tissues. Upregulated expression of EGFL6 was found in a variety of cancer cell types, such as ovarian cancer and lung cancer. Unlike VEGF, which was expressed in ovarian cancer tissues and in healing wounds, EGFL6 was expressed mainly in tumor-associated...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Anil Sood, Ningyan Zhang

Keywords(s):

Category(s): Biologics, Therapeutics, Oncology

Synthetic Antifungal Peptides

Novel antifungal compositions that inhibit fungal growth which have both medical and non-medical utility and applications Inventors at the University of Texas Health Science Center at Houston have developed a series of novel peptide compounds to inhibit fungal growth. The peptides are based on the bacteriocin EntV, which is secreted by Enterococcus...

Published: 10/21/2024 | Inventor(s): Danielle Garsin, Michael Lorenz

Keywords(s):

Category(s): Biologics, Therapeutics

LGR4 Specific Monoclonal Antibodies and Their Use

Researchers at UTHealth have isolated and characterized monoclonal antibodies as well as antibody fragments that specifically binding to LGR4, a 7TM receptor that is highly expressed in major types of solid tumors, including but not limited to colorectal cancer, non-small cell lung cancer, and ovarian cancer. These LGR4 specific monoclonal antibodies...

Published: 10/21/2024 | Inventor(s): Qingyun (Jim) Liu

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics, Diagnostics, Research Materials

R-Spondin Polypeptides and Drug Conjugates for Cancer Treatment

R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGR4/5/6 and RNF43/ZNRF3 and potentiating Wnt signaling. UTHealth pioneering scientist engineered and fused an immunoglobin Fc domain to the mutated RSPOs (RSPO peptibodies). RSPO peptibodies can binds to LGR4/5/6 with high affinity but exhibit reduced...

Published: 10/21/2024 | Inventor(s): Qingyun (Jim) Liu

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use

Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal the role of OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...

Published: 10/21/2024 | Inventor(s): Zhiqiang An

Keywords(s):

Category(s): Diagnostics, Therapeutics, Biologics, Oncology

1 2